TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Statin Therapy to Improve Atherosclerosis in HIV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Men and women age 18-60 with previously diagnosed HIV disease~2. Subclinical coronary artery disease as defined by presence of one or more plaque on coronary CTA without history of cardiac events or cardiac symptoms and no evidence of critical coronary stenosis. Target to background ratio (TBR) as determined by PET of \> 1.6.~3. Stable anti-retroviral (ARV) therapy as defined by no changes in ARV regimen for \>6 months~4. LDL-cholesterol \>70 mg/dL and \<130 mg/dL~Exclusion criteria:~1. History of acute coronary syndrome~2. Contraindication to statin therapy~3. Current statin use~4. AST or ALT two times greater than the upper limit of normal or receiving treatment for active liver disease~5. Renal disease or creatinine \>1.5 mg/dL (given the risk of contrast nephropathy during CT angiography of the heart)~6. Infectious illness within past 3 months~7. Contraindication to beta-blocker (including moderate to severe asthma or heart block) or nitroglycerin use as these drugs are given as part of the standard cardiac CT protocol. Previous allergic reaction to beta blocker or nitroglycerin.~8. Body weight greater than 300 lbs due to CT scanner table limitations~9. Patients with previous allergic reactions to iodine-containing contrast media~10. Active illicit drug use~11. Patients who report any significant radiation exposure over the course of the year prior to randomization. Significant exposure is defined as:~    1. More than 2 percutaneous coronary interventions (PCI) within 12 months of randomization~   2. More than 2 myocardial perfusion studies within the past 12 months~   3. More than 2 CT angiograms within the past 12 months~   4. Any subjects with history of radiation therapy.~12. Patients already scheduled or being considered for a procedure or treatment requiring significant radiation exposure (e.g., radiation therapy, PCI, or catheter ablation of arrhythmia) within 12 months of randomization~13. Pregnancy or breastfeeding~14. Coronary artery luminal narrowing \>70% seen on coronary CTA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): 20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Computer-Aided Prevention System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At high risk of stroke:~  * Already suffered a stroke or Transient Ischemic Attack (TIA) or~ * At least two risk factors for stroke:~    * High blood pressure~   * Overweight~   * Low physical activity~   * Smoking~   * Unhealthy diet~Exclusion Criteria:~* Inability to fill out or to understand the informed consent~* No signed informed consent~* Dementia

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care (SC) (Type: ACTIVE_COMPARATOR): None
- Interventional care (IC) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Solution and Dexamethasone in Mucolox™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older.~* Patients with symptomatic biopsy proven Oral Inflammatory Ulcerative Diseases (worst VAS sensitivity score ≥ 7 over the last week).~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Patients already on topical or systemic steroids.~* Inability to comply with study instructions.~* Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.~* VAS sensitivity score \< 7.~* Pregnant women. A urine pregnancy test will be performed for women of child bearing potential.~* Allergy to fluconazole.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- dexamethasone 0.5mg/5ml solution in Mucolox™ (group A) (Type: EXPERIMENTAL): Dexamethasone solution (0.5mg/5ml) in Mucolox™ three times a day (TID) swish and spit for 4 weeks
- dexamethasone 0.5mg/5ml solution (Arm B) (Type: ACTIVE_COMPARATOR): Dexamethasone solution (0.5mg/5ml) TID swish and spit for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Substrate Cycling in Energy Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~We will study male and female burned patients from 20 KG (based on blood requirement) in weight. Patients will be studied between days 12-15 after the initial surgery and will have burns constituting \>40% of the body surface. Volunteers will be determined as healthy utilizing history, physical examination and screening laboratory values assessing liver and renal function, coagulation and platelet function.~Exclusion Criteria:~1.Sulfide or iodide allergies 2.Respiratory Insufficiency 3.Multiple Fractures 4.History of Cancer in the last 5 years 5.Diabetes Mellitus 6.Bilirubin \>3.0 mg/dl 7.Associated head injuries requiring specific therapy 8.Associated injuries to chest or abdomen requiring surgery 9.Serum creatine \> 3.0 mg/dl after fluid resuscitation 10.Receipt of any experimental drug other than ones supplied with two months of this study 11.Any metal in body including rods, neurofibrilators, pacemakers, etc. 12.Orthopedic casting which would prevent placement in MRI 13.Hepatitis 14.Abnormal EKG 17. Bruits over the femoral artery 18. Electrical burn 19. Patients unable to lie still without heavy sedation will not be used for the MRS portion of the study.~-

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* participants will be HIV and HSV-2 seropositive~Exclusion Criteria:~* pregnancy, CD4 count \<200, on ART

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Large-scale Brain Organization During Cognitive Control in ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 8-12 years old~* Diagnosis of ADHD (for ADHD group); ADHD group only can have comorbid Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnoses of oppositional defiant disorder, conduct disorder, depressive disorders, or anxiety disorders~* ADHD subjects must never have been treated with medication for their ADHD~Exclusion Criteria:~* Wechsler Intelligence Scale for Children-Fifth Edition Full-Scale Intelligence Quotient (IQ) \< 80~* Wechsler Individual Achievement Test-Third Edition Word Reading \< 85~* Any neurologic or developmental disabilities~* Any reading or learning disabilities~* Visual impairment that cannot be corrected-to-normal~* Color blindness~* Documented hearing impairment greater than 25 decibels (dB) loss in either year~* Have already gone through puberty (Tanner Stage II or higher)~* Medical contraindication to MRI~* Any psychoactive medication

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Placebo, then Methylphenidate (Type: PLACEBO_COMPARATOR): All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
- Methylphenidate, then Placebo (Type: EXPERIMENTAL): All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switching Study From Warfarin to Rivaroxaban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 45 years of age;~* Normal body weight: BMI (body mass index) between 18 and 29 kg/m2;~* Pharmacogenetics: subjects who are homozygous for the wildtype allele 2C9\*1 and who are carriers of the C-allele at positions 6484 and 7566 of the VKORC1 (vitamin K epoxide reductase) gene, respectively~Exclusion Criteria:~* Relevant deviation from the normal range in the clinical examination;~* Relevant deviation from the normal range in clinical chemistry, hematology or urinalysis;~* Resting heart rate in the awake subject below 45 BPM (beats per minute) or above 90 BPM;~* Systolic blood pressure below 100 mmHg or above 140 mmHg; and Diastolic blood pressure above 85 mmHg;~* Relevant pathological changes in the ECG (electrocardiogram) such as a second or third-degree AV block, prolongation of the QRS (QRS complex in ECG) complex over 120 msec or of the QT / QTc-interval over 450 msec (QT interval in ECG, QTc interval corrected for heart rate);~* Subject is tested to be HIV-1/2Ab, p24Ag, HbsAg or HCV-Ab positive;~* Known coagulation disorders (e.g. von Willebrand's disease, haemophiliac);~* Known disorders with increased bleeding risks (e.g. periodontosis, hemorrhoids, acute gastritis, peptic ulcer);~* Known sensitivity to common causes of bleeding (e.g. nasal);~* Recent or planned surgical or diagnostic procedures at the central nervous system (CNS) or eye;~* Subjects with hyperlipidemia (Coumadin / warfarin warning)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Warfarin followed by Rivaroxaban (Xarelto, BAY59-7939) (Type: EXPERIMENTAL): Days -6 and -5: 10 mg warfarin once daily or lower depending on international normalized ratio (INR); Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 20 mg rivaroxaban once daily; Day 5: 10 mg vitamin K once daily
- Warfarin followed by Placebo (Type: PLACEBO_COMPARATOR): Days -6 and -5: 10 mg warfarin once daily or lower depending on INR; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 1 tablet matching placebo once daily; Day 5: 10 mg vitamin K once daily
- Rivaroxaban (Xarelto, BAY59-7939) (Type: ACTIVE_COMPARATOR): Days 0 to 3: 20 mg rivaroxaban once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of Long Term Safety Evaluation of Alirocumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~Participants with heFH who had completed one of the four parent studies (EFC12492, R727-CL-1112, EFC12732 and LTS11717).~Exclusion criteria:~Significant protocol deviation in the parent study; Any permanent treatment discontinuation from the parent study.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alirocumab 75 or 150 mg Q2W (Type: EXPERIMENTAL): Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Folic Acid Supplementation in Phenytoin Induced Gingival Overgrowth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 6-15 yr~* Started on phenytoin within 1 mo of enrollment~Exclusion Criteria:~* Not willing to participate~* On other folic acid antagonists e.g. anti-neoplastic drugs for \>/= 2 wks during last 3 months~* Pre-existing gingival over-growth due to other cause

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral folic acid
- 2 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participants who were aged from 20 to 65 years and met the diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) were eligible for the recruitment to the clinical trial.~* They also fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability.~Exclusion Criteria:~* Any DSM-IV-TR Axis I disorder other than schizophrenia, except comorbid obsessive-compulsive disorder, anxiety disorder, eating disorders or impulse control disorders if they had been stable and had not been primary focus of treatment over the previous 6 months~* An imminent risk of suicide or a danger to self or others~* Pregnancy or lactation~* Intolerance or lack of response to quetiapine IR~* Use of cytochrome P450 3A4 inhibitors or inducers in the 14 days preceding enrolment~* Administration of a depot antipsychotic injection within one dosing interval before recruitment~* Unstable or inadequately treated medical illness as judged by the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine XR (Type: EXPERIMENTAL): Patients had schizophrenia and fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability (N=61). They will receive the intervention of administration of quetiapine XR.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C infection of genotype 1~2. Therapy-naïve to interferon, pegylated interferon, and ribavirin~3. HCV viral load \> 100.000 IU/ml at screening~4. Liver biopsy or fibroscan within two years prior to screening that provides evidence of any degree of fibrosis or cirrhosis~5. Normal retinal finding on fundoscopy within 6 months prior to Day 1~6. Age 18 to 70 years~Exclusion criteria:~1. HCV of mixed genotype (1/2, 1/3, and 1/4) .~2. Patients who have been previously treated with at least one dose of any protease inhibitor~3. Evidence of liver disease due to causes other than chronic HCV infection~4. Positive for HIV-1 or HIV-2 antibodies~5. Hepatitis B virus (HBV) infection~6. Decompensated liver disease, or history of decompensated liver disease~7. Active malignancy or history of malignancy within the last 5 years~8. History of alcohol or drug abuse (except cannabis) within the past 12 months.~9. Body Mass Index \< 18 or \> 35 kg/m2.~10. Usage of any investigational drugs within 30 days prior to enrolment~11. Alpha fetoprotein value \>100ng/mL at screening;~12. Total bilirubin \> 1.5 x ULN with ratio of direct/indirect \> 1.~13. ALT or AST level \> 10 x ULN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- short arm (Type: EXPERIMENTAL): patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
- long arm (Type: EXPERIMENTAL): patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hemodialysis patients undergoing 4-hour-long HD thrice a week for at least 2 years~* With an average serum potassium level (immediately before dialysis on the first day of the week) of \<6.5 mEq/l over the previous 2 months~* With a 24-hour urine output of \<500 ml~Exclusion Criteria:~* A history of noncompliance~* Unstable vascular access~* Hypotension~* Hepatic failure~* Active cancer~* Any life-threatening disease other than ESRD

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- spironolactone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a diagnosis of pathologically confirmed NSCLC by tumor biopsy and/or fine-needle aspiration.~* The patient has a diagnosis of American Joint Committee on Cancer (AJCC) 8th Edition stage IV NSCLC.~* The patient receives 3rd generation EGFR-TKI in the first line setting.~* The patient is ≥18 years of age and ≤75 years of age at the time of screening.~* The patient's Karnofsky performance score (KPS) is ≥70 at study entry.~* The patient has adequate baseline tumor assessment before initiation of 3rd generation EGFR-TKI.~* The patient has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.~* The patient presents with a residual oligometastatic state after 3rd generation EGFR-TKI therapy that would be amenable to consolidative SRT in the opinion of the investigator.~* The patient has signed informed consent.~* EGFR Exon19 deletion or Exon21 L858R mutation~Exclusion Criteria:~* History of another malignancy or concurrent malignancy. Patients with cervical carcinoma in situ or adequately treated basal cell carcinoma who have been disease free for \> 5 years are eligible.~* The patient is pregnant (confirmed by serum b-HCG if applicable) or is breastfeeding.~* Patients with uncontrolled epilepsy, mental disorders, drug abuse, or social condition that may affect compliance or ability to sign a written informed consent in the opinion of the investigator.~* Patients with residual metastatic disease after 3rd generation EGFR-TKI therapy that is deemed not amenable to consolidative SRT.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 3rd generation EGFR-TKI+ SRT (Type: EXPERIMENTAL): Patients were treated with the intent to ablate all residual disease with consolidative SRT. EGFR-TKI treatment was continued during and after consolidative SRT until disease progression or intolerable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete